Compare THRY & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 148.7M |
| IPO Year | 2020 | 2001 |
| Metric | THRY | CGEN |
|---|---|---|
| Price | $2.61 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.33 | $4.00 |
| AVG Volume (30 Days) | ★ 1.7M | 322.2K |
| Earning Date | 04-30-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $112.37 |
| P/E Ratio | $283.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $1.13 |
| 52 Week High | $15.60 | $2.38 |
| Indicator | THRY | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 54.55 |
| Support Level | $1.91 | $1.47 |
| Resistance Level | $3.69 | $2.35 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 15.56 | 34.86 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.